Share on LinkedInShare on LinkedIn

ARTICLE · 31 JULY 2015

Third Circuit Extends Actavis To Reverse Settlement Agreements Involving Non-Cash Consideration

The plaintiffs are direct purchasers of Lamictal, a brand-name drug used to treat epilepsy and bipolar disorder, from defendant GlaxoSmithKline (GSK).

United StatesIntellectual Property

King Drug Company of Florence, Inc. v. Smithkline Beecham Corp. d/b/a GlaxoSmithKline

Addressing for the first time whether reverse settlement agreements involving non-cash consideration merit antitrust scrutiny, the U.S. Court of Appeals for the Third Circuit reversed the district court, applying the reasoning set forth in the Supreme Court's Actavis decision to hold that non-cash payments were subject to the same rule of reason analysis as cash payments. King Drug Company of Florence, Inc. v. Smithkline Beecham Corp. d/b/a GlaxoSmithKline, Case No. 14-1243 (3rd Cir., Jun. 26, 2015) (Scirica, J).

The plaintiffs are direct purchasers of Lamictal, a brand-name drug used to treat epilepsy and bipolar disorder, from defendant GlaxoSmithKline (GSK). GSK developed Lamictal and held a patent for its active ingredient, lamotrigine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from